Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin

Antiviral Research

Volumn 90, Issue 1, 2011, Pages 22-32

  Kumaki, Yohichi ^a   Wandersee, Miles K ^a   Smith, Aaron J ^a   Zhou, Yanchen ^b,c   Simmons, Graham ^b,c   Nelson, Nathan M ^a   Bailey, Kevin W ^a   Vest, Zachary G ^a   Li, Joseph K K ^a   Chan, Paul Kay Sheung ^d   Smee, Donald F ^a   Barnard, Dale L ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

BALB c mouse; SARS CoV; Urtica dioica agglutinin (UDA)

Indexed keywords

PLACEBO; PLANT LECTIN; UNCLASSIFIED DRUG; URTICA DIOICA AGGLUTININ; URTICA DIOICA EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IN VITRO STUDY; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; URTICA DIOICA; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION; WEIGHT REDUCTION;

MUS; NIDOVIRALES; SARS CORONAVIRUS; URTICA DIOICA;

EID: 79953689569     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.02.003     Document Type: Article

References (56)

1. Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003, 300(5626):1763-1767.
2. Balzarini J. Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?. Antivir. Chem. Chemother. 2007, 18(1):1-11.
3. Barnard D.L., Day C.W., Bailey K., Heiner M., Montgomery R., Lauridsen L., Chan P.K., Sidwell R.W. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir. Chem. Chemother. 2006, 17(5):275-284.
4. Barnard D.L., Day C.W., Bailey K., Heiner M., Montgomery R., Lauridsen L., Winslow S., Hoopes J., Li J.K., Lee J., Carson D.A., Cottam H.B., Sidwell R.W. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res. 2006, 71(1):53-63.
5. Barnard D.L., Hubbard V.D., Burton J., Smee D.F., Morrey J.D., Otto M.J., Sidwell R.W. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-d-N4-hydroxycytidine. Antivir. Chem. Chemother. 2004, 15(1):15-22.
6. Barnard D.L., Hubbard V.D., Smee D.F., Sidwell R.W., Watson K.G., Tucker S.P., Reece P.A. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob. Agents Chemother. 2004, 48(5):1766-1772.
7. Barnard D.L., Kumaki Y. Development in the search for the small-molecule inhibitors for treatment of severe acute respiratory syndrome coronavirus. Antiviral Research: Strategies in Antiviral Drug Discovery 2009, 209-222. ASM Press, Washington, DC. R.L. LaFemina (Ed.).
8. Beintema J.J., Peumans W.J. The primary structure of stinging nettle (Urtica dioica) agglutinin. A two-domain member of the hevein family. FEBS Lett. 1992, 299(2):131-134.
9. Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., Walmsley S.L., Mazzulli T., Avendano M., Derkach P., Ephtimios I.E., Kitai I., Mederski B.D., Shadowitz S.B., Gold W.L., Hawryluck L.A., Rea E., Chenkin J.S., Cescon D.W., Poutanen S.M., Detsky A.S. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003, 289(21):2801-2809.
10. Bosch B.J., Martina B.E., Van Der Zee R., Lepault J., Haijema B.J., Versluis C., Heck A.J., De Groot R., Osterhaus A.D., Rottier P.J. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(22):8455-8460.
11. Cavanaugh P.F., Moskwa P.S., Donish W.H., Pera P.J., Richardson D., Andrese A.P. A semi-automated neutral red based chemosensitivity assay for drug screening. Invest. New Drugs 1990, 8(4):347-354.
12. Chen J., Subbarao K. The immunobiology of SARS. Annu. Rev. Immunol. 2007, 25:443-472.
13. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003, 361(9374):2045-2046.
14. Connor R.I., Chen B.K., Choe S., Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206(2):935-944.
15. Day C.W., Baric R., Cai S.X., Frieman M., Kumaki Y., Morrey J.D., Smee D.F., Barnard D.L. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology 2009, 395(2):210-222.
16. Ding Y., He L., Zhang Q., Huang Z., Che X., Hou J., Wang H., Shen H., Qiu L., Li Z., Geng J., Cai J., Han H., Li X., Kang W., Weng D., Liang P., Jiang S. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J. Pathol. 2004, 203(2):622-630.
17. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348(20):1967-1976.
18. Galelli A., Truffa-Bachi P. Urtica dioica agglutinin. A superantigenic lectin from stinging nettle rhizome. J. Immunol. 1993, 151(4):1821-1831.
19. Groneberg D.A., Fischer A., Chung K.F., Daniel H. Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport. Am. J. Respir. Cell Mol. Biol. 2004, 30(3):251-260.
20. Groneberg D.A., Witt C., Wagner U., Chung K.F., Fischer A. Fundamentals of pulmonary drug delivery. Respir. Med. 2003, 97(4):382-387.
21. Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W., Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W., Shortridge K.F., Yuen K.Y., Peiris J.S., Poon L.L. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003, 302(5643):276-278.
22. Ho J.C., Ooi G.C., Mok T.Y., Chan J.W., Hung I., Lam B., Wong P.C., Li P.C., Ho P.L., Lam W.K., Ng C.K., Ip M.S., Lai K.N., Chan-Yeung M., Tsang K.W. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am. J. Respir. Crit. Care Med. 2003, 168(12):1449-1456.
23. Ho T.Y., Wu S.L., Chen J.C., Wei Y.C., Cheng S.E., Chang Y.H., Liu H.J., Hsiang C.Y. Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2006, 69(2):70-76.
24. Jeffers S.A., Tusell S.M., Gillim-Ross L., Hemmila E.M., Achenbach J.E., Babcock G.J., Thomas W.D., Thackray L.B., Young M.D., Mason R.J., Ambrosino D.M., Wentworth D.E., Demartini J.C., Holmes K.V. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(44):15748-15753.
25. Jiang Y., Xu J., Zhou C., Wu Z., Zhong S., Liu J., Luo W., Chen T., Qin Q., Deng P. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am. J. Respir. Crit. Care Med. 2005, 171(8):850-857.
26. Keyaerts E., Vijgen L., Maes P., Neyts J., Van Ranst M. Growth kinetics of SARS-coronavirus in Vero E6 cells. Biochem. Biophys. Res. Commun. 2005, 329(3):1147-1151.
27. Keyaerts E., Vijgen L., Pannecouque C., Van Damme E., Peumans W., Egberink H., Balzarini J., Van Ranst M. Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res. 2007, 75(3):179-187.
28. Krokhin O., Li Y., Andonov A., Feldmann H., Flick R., Jones S., Stroeher U., Bastien N., Dasuri K.V., Cheng K., Simonsen J.N., Perreault H., Wilkins J., Ens W., Plummer F., Standing K.G. Mass spectrometric characterization of proteins from the SARS virus: a preliminary report. Mol. Cell. Proteomics 2003, 2(5):346-356.
29. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., Anderson L.J. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348(20):1953-1966.
30. Kumaki Y., Day C.W., Wandersee M.K., Schow B.P., Madsen J.S., Grant D., Roth J.P., Smee D.F., Blatt L.M., Barnard D.L. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochem. Biophys. Res. Commun. 2008, 371(1):110-113.
31. Lau S.K., Woo P.C., Li K.S., Huang Y., Tsoi H.W., Wong B.H., Wong S.S., Leung S.Y., Chan K.H., Yuen K.Y. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(39):14040-14045.
32. Leonard J.N., Schaffer D.V. Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther. 2006, 13(6):532-540.
33. Li D., Wu N., Yao H., Bader A., Brockmeyer N.H., Altmeyer P. Association of RANTES with the replication of severe acute respiratory syndrome coronavirus in THP-1 cells. Eur. J. Med. Res. 2005, 10(3):117-120.
34. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426(6965):450-454.
35. Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., Wang H., Crameri G., Hu Z., Zhang H., Zhang J., McEachern J., Field H., Daszak P., Eaton B.T., Zhang S., Wang L.F. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005, 310:676-679.
36. Marzi A., Gramberg T., Simmons G., Moller P., Rennekamp A.J., Krumbiegel M., Geier M., Eisemann J., Turza N., Saunier B., Steinkasserer A., Becker S., Bates P., Hofmann H., Pohlmann S. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J. Virol. 2004, 78(21):12090-12095.
37. O'Keefe B.R., Giomarelli B., Barnard D.L., Shenoy S.R., Chan P.K., McMahon J.B., Palmer K.E., Barnett B.W., Meyerholz D.K., Wohlford-Lenane C.L., McCray P.B. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J. Virol. 2010, 84(5):2511-2521.
38. Peiris J.S., Chu C.M., Cheng V.C., Chan K.S., Hung I.F., Poon L.L., Law K.I., Tang B.S., Hon T.Y., Chan C.S., Chan K.H., Ng J.S., Zheng B.J., Ng W.L., Lai R.W., Guan Y., Yuen K.Y. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003, 361:1767-1772.
39. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., Nicholls J., Yee W.K., Yan W.W., Cheung M.T., Cheng V.C., Chan K.H., Tsang D.N., Yung R.W., Ng T.K., Yuen K.Y. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361:1319-1325.
40. Ritchie G., Harvey D.J., Feldmann F., Stroeher U., Feldmann H., Royle L., Dwek R.A., Rudd P.M. Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein. Virology 2010, 399(2):257-269.
41. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300(5624):1394-1399.
42. Sidwell R.W., Bailey K.W., Wong M.H., Huffman J.H. In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin. Chemotherapy 1995, 41(6):455-461.
43. Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L., Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(33):11876-11881.
44. Simmons G., Reeves J.D., Rennekamp A.J., Amberg S.M., Piefer A.J., Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(12):4240-4245.
45. Sui J., Li W., Murakami A., Tamin A., Matthews L.J., Wong S.K., Moore M.J., Tallarico A.S., Olurinde M., Choe H., Anderson L.J., Bellini W.J., Farzan M., Marasco W.A. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(8):2536-2541.
46. Tsang K., Seto W.H. Severe acute respiratory syndrome: scientific and anecdotal evidence for drug treatment. Curr. Opin. Invest. Drugs 2004, 5(2):179-185.
47. Tsang K.W., Ho P.L., Ooi G.C., Yee W.K., Wang T., Chan-Yeung M., Lam W.K., Seto W.H., Yam L.Y., Cheung T.M., Wong P.C., Lam B., Ip M.S., Chan J., Yuen K.Y., Lai K.N. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003, 348(20):1977-1985.
48. Tsui P.T., Kwok M.L., Yuen H., Lai S.T. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg. Infect. Dis. 2003, 9(9):1064-1069.
49. Van Damme E.J., Broekaert W.F., Peumans W.J. The Urtica dioica agglutinin is a complex mixture of isolectins. Plant Physiol. 1988, 86(2):598-601.
50. van der Meer F.J., de Haan C.A., Schuurman N.M., Haijema B.J., Peumans W.J., Van Damme E.J., Delputte P.L., Balzarini J., Egberink H.F. Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture. Antiviral Res. 2007, 76(1):21-29.
51. Yang H., Yang M., Ding Y., Liu Y., Lou Z., Zhou Z., Sun L., Mo L., Ye S., Pang H., Gao G.F., Anand K., Bartlam M., Hilgenfeld R., Rao Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(23):13190-13195.
52. Yang Z.Y., Huang Y., Ganesh L., Leung K., Kong W.P., Schwartz O., Subbarao K., Nabel G.J. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J. Virol. 2004, 78(11):5642-5650.
53. Ye J., Zhang B., Xu J., Chang Q., McNutt M.A., Korteweg C., Gong E., Gu J. Molecular pathology in the lungs of severe acute respiratory syndrome patients. Am. J. Pathol. 2007, 170(2):538-545.
54. Yen Y.T., Liao F., Hsiao C.H., Kao C.L., Chen Y.C., Wu-Hsieh B.A. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J. Virol. 2006, 80(6):2684-2693.
55. Zhou Y., Lu K., Pfefferle S., Bertram S., Glowacka I., Drosten C., Pohlmann S., Simmons G. A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. J. Virol. 2010, 84(17):8753-8764.
56. Ziolkowska N.E., O'Keefe B.R., Mori T., Zhu C., Giomarelli B., Vojdani F., Palmer K.E., McMahon J.B., Wlodawer A. Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 2006, 14(7):1127-1135.